betibeglogene autotemcel
betibeglogene autotemcel is listed in the FDA National Drug Code directory with 2 NDC codes, marketed under brand name including Zynteglo. Available dosage form: suspension.
Drug Details
- Generic Name
- betibeglogene autotemcel
- Brand Names
- Zynteglo
- Application Number
- BLA125717
- Sponsor
- Genetix Biotherapeutics Inc.
- NDC Codes
- 2
- Dosage Forms
- SUSPENSION
- Routes
- INTRAVENOUS
- Active Ingredients
- BETIBEGLOGENE AUTOTEMCEL
Indications and Usage
1 INDICATIONS AND USAGE ZYNTEGLO is indicated for the treatment of adult and pediatric patients with β-thalassemia who require regular red blood cell (RBC) transfusions. ZYNTEGLO is an autologous hematopoietic stem cell-based gene therapy indicated for the treatment of adult and pediatric patients with β-thalassemia who require regular red blood cell (RBC) transfusions. ( 1 )